Zevra Therapeutics (ZVRA) Earnings Date & Reports

Key Takeaways

• Zevra reported third-quarter 2026 net revenue of $37.8 million, up 45% from $26.1 million in the same period last year.
• Lead product MIPLYFFA, used to treat Niemann-Pick disease type C (NPC), generated $34.0 million in net U.S. revenue.
• Diluted earnings per share (EPS) of $0.26 topped consensus estimates of roughly $0.14–$0.16, while revenue also beat expectations near $37.1 million.
• The company ended the quarter with $270.9 million in cash, cash equivalents, and investments, strengthening its runway for pipeline development.
• Total operating expenses rose to $24.1 million, reflecting increased investment in commercialization and R&D (research and development).
• For more detail on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Discover additional trading ideas by exploring Trending AI Robots.

Earnings Context and Why It Matters

Zevra Therapeutics is a commercial-stage rare-disease company whose investment story hinges on the launch trajectory of MIPLYFFA (arimoclomol), its FDA-approved therapy for NPC, a rare and progressive neurodegenerative disorder. Because NPC has a small, identifiable patient population, quarterly revenue is closely watched as a direct read on commercial execution, prescription uptake, and payer coverage. Prior quarters showed steady growth, and this report confirms whether momentum is accelerating. For investors, the results also clarify whether rising operating costs are being matched by top-line expansion and whether the balance sheet remains sufficient to fund the celiprolol program and European regulatory efforts.

Reported Results

Zevra reported third-quarter 2026 net revenue of $37.8 million, a 45% increase from $26.1 million in the year-ago quarter. The result was driven by $34.0 million in net U.S. MIPLYFFA revenue, along with $0.2 million from OLPRUVA (sodium phenylbutyrate) and $3.6 million in net reimbursements from its global Expanded Access Program (EAP).

Net income came in at $19.2 million, or $0.31 per basic and $0.26 per diluted share, compared with a net loss of $0.5 million, or $(0.01) per share, in Q3 2025. The quarter included $5.1 million in non-cash income from fair value adjustments tied to warrant and contingent value rights (CVR) liabilities. GAAP (Generally Accepted Accounting Principles) EPS of $0.26 exceeded consensus estimates of about $0.14–$0.16, while revenue also topped the roughly $37.1 million consensus.

Total operating expenses were $24.1 million, up from $20.4 million a year earlier. R&D expense increased to $4.9 million, and selling, general, and administrative (SG&A) expense rose to $19.1 million, reflecting higher commercial and infrastructure costs. Zevra closed the quarter with $270.9 million in cash, cash equivalents, and investments.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market using technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs with customizable filters, including industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Zevra, it can help identify comparable opportunities and refine watchlists with data-backed signals.

Market Reaction and Investor Sentiment

Heading into the report, sentiment was cautiously optimistic, with analysts raising EPS estimates in the weeks before the release and the stock trading near $10. After the results, early reports indicated the shares moved higher in after-hours trading, as investors responded to a top-and-bottom-line beat and continued MIPLYFFA momentum. The stock has been volatile in recent months, so traders are likely weighing strong commercial execution against higher operating expenses and the still-pending European regulatory decision for arimoclomol. The key question for the market is whether prescription growth can be sustained while costs remain controlled.

Forward Outlook and Key Factors to Monitor

Several catalysts are likely to shape Zevra's story in the coming quarters. First, investors will watch the trajectory of MIPLYFFA prescription enrollment forms, which reached 197 cumulatively since launch, with 13 new forms added in Q3 2026. Patient retention and expanding payer coverage — currently around 69% — are important signals for future revenue durability.

Second, the company is pursuing European access for arimoclomol through a re-examination of its Marketing Authorisation Application (MAA) by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). An approval could meaningfully expand the product's addressable market.

Third, Zevra anticipates filing a supplemental New Drug Application (sNDA) with the FDA in Q1 2027 to potentially expand MIPLYFFA's label to infants under 24 months of age, following a recent Type B meeting.

Finally, the Phase 3 DiSCOVER trial of celiprolol for Vascular Ehlers-Danlos Syndrome (VEDS) continues enrollment, with 72 patients enrolled and four confirmed events as of quarter-end. With a strong cash position, Zevra has flexibility to advance these priorities, though rising SG&A and R&D costs will remain a key area for investors to monitor.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations